Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusions
These studies demonstrate that NTRK wild-type receptors are important drivers of brain metastatic colonization and progression in different subtypes of lung cancer, independent of their driver alterations. Thus, they provide rationale to expand the use of FDA-approved NTRK inhibitors with brain penetrance for the prevention of CNS metastases.
Authors
- Diana M. Cittelly (ORCID: https://orcid.org/0000-0002-8392-0800)
- Jenny A. Jaramillo-Gómez (ORCID: https://orcid.org/0009-0005-6416-0948)
- Ricaurte Alejandro Marquez-Ortíz (ORCID: https://orcid.org/0000-0002-7188-6158)
- Maria Contreras-Zarate
- Andre Navarro (ORCID: https://orcid.org/0000-0002-7360-3369)
- Trinh C Pham
- Stella Koliavas
- D. Ross Camidge
- Raphael A Nemenoff
- D. Ryan Ormond
Institutions
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-03-20
- DOI
- https://doi.org/10.64898/2026.03.18.711213
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00